Plendil patent ruling
Executive Summary
Mutual's ANDA for felodipine extended-release does not infringe an AstraZeneca patent for the calcium channel blocker Plendil, a D.C. federal appeals court rules Sept. 30. The court reversed a Philadelphia federal judge's ruling that Mutual infringed patent no. 4,803,081, which runs until October 2007...